CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Zura Bio Ltd (ZURA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Zura Bio Ltd (ZURA)

Biological Products, (No Diagnostic Substances) · market cap $410M · as of 2026-11-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-05-15 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Zura Bio (ZURA) is a clinical-stage biologics company whose lead asset, tibulizumab, is in Phase 2 for systemic sclerosis (SSc), with two separate Phase 2 dose arms listed in hidradenitis suppurativa (HS). At ~$1.40 per share and a ~$135M market cap, the equity trades below its reported $187.7M cash balance (net debt -$187.7M), so the market is assigning a negative enterprise value to the pipeline. The only dated clinical catalyst in our calendar is an estimated Phase 2 SSc readout around 2027-05-15. Our calendar also shows estimated earnings on 2026-11-12, shortly after a completed 2026-10-27 report, which may be an estimate artifact.
The catalyst path
  • 2027-05-15 (est.)Phase 2 · Tibulizumabimp 7/10
Pipeline
AssetPhaseIndication
Tibulizumab Dose APhase 2Hidradenitis Suppurativa (HS)
TibulizumabPhase 2Systemic Sclerosis (SSc)
Tibulizumab Dose BPhase 2Hidradenitis Suppurativa (HS)
Price & technical context
3-month
-78.2%
6-month
-73.7%
12-month
-73.2%
52-wk range
$1.24–$7.04
vs 50-day MA
-69.1%
vs 200-day MA
-75.6%
Realized vol
144.6%
Max drawdown
-82.4%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ZURA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.